India, Oct. 23 -- Shares of several biotech companies moved higher following corporate, financing and clinical developments. Bolt Biotherapeutics gained after announcing a reverse merger with Prana Therapies and a $120 million private placement, Lycia Therapeutics surged in its Nasdaq IPO debut, Lucid Diagnostics rose on Medicare reimbursement for EsoGuard, and Genmab advanced after positive Phase 3 ovarian cancer data for Rina-S.
Read on.....
Bolt Biotherapeutics, Inc. (BOLT)
Shares of Bolt Biotherapeutics surged about 66% on Friday after the company announced an agreement to acquire Prana Therapies through a stock-for-stock reverse merger. The transaction is intended to advance Prana's PRA-216 antibody program, which targets asthma, CO...